Evidence map›Paper›PMID 42610673›Full record

ReviewThoracic cancer2026

Multidisciplinary Team Care for Early-Stage Lung Cancer in Low- and Middle-Income Countries and Emerging Economies: Current Position and Call for Action.

Luiz Henrique Araujo, Francisco J Orlandi, Adli Azam, Lucia Viola, Yasser Elkerm, Jorge Alatorre-Alexander, Sevin Başer Öncel, Gustavo A Lyons, Xiao Li, Trung Lam Quoc and 2 more

Abstract readReview
In one paragraph

Review in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Luiz Henrique AraujoDepartment of Medical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0001-9486-7139
Francisco J OrlandiLung Cancer Unit, National Thorax Institute, Santiago, Chile.
Adli AzamDepartment of Cardiothoracic Surgery, Gleneagles Hospital Johor, Iskandar Puteri, Malaysia.
Lucia ViolaCenter of Expertise in Thoracic Oncology Oncotórax, Fundación Neumológica Colombiana, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center, Bogotá, Colombia.
Yasser ElkermDepartment of Clinical Oncology, Alexandria University, Alexandria, Egypt.
Jorge Alatorre-AlexanderMedical Oncology Department, Instituto Nacional de Enfermedades Respiratorias (INER), Mexico City, Mexico.
Sevin Başer ÖncelDepartment of Pulmonary Medicine, Pamukkale University, Denizli, Türkiye.
Gustavo A LyonsThoracic Oncology Center, British Hospital, Buenos Aires, Argentina.
Xiao LiDepartment of Thoracic Surgery, Peking University People's Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-0455-0355
Trung Lam QuocFaculty of Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
Anusheel MunshiDepartment of Radiation Oncology, BLK MAX Hospital, New Delhi, India.
Francisco GonzalezMedical Affairs, AstraZeneca, Baar, Switzerland.

Funding

AstraZeneca
6 · The paper itself

Abstract

Lung cancer (LC) is a complex cancer marked by poor prognosis. Low- and middle-income countries (LMICs) and emerging economies have witnessed a growing burden of LC in recent years due to low symptom awareness, rising tobacco use, air pollution, and pulmonary infections. Managing LC optimally requires a multidisciplinary team (MDT) approach to support accurate diagnosis, staging, and treatment. MDT presentation has been linked to timely diagnosis and staging, receipt of surgery, and survival benefits in early-stage LC (ESLC). However, delivering high-quality ESLC care through an MDT approach remains challenging in LMICs and emerging economies. Weak organizational structure, fragmentation of the financing and health system, oncology workforce deficits, and unawareness of the potential impact of MDTs hinder optimal care. Systematic identification, analysis, and reporting of barriers to ESLC care are critical for improving care quality and informing effective corrective interventions. This article aimed to explore barriers to MDT implementation that are unique to the care of patients with ESLC in LMICs and emerging economies and developed evidence-informed recommendations for strengthening MDT care pathways. Key focus areas addressed by these recommendations include the composition of the MDT panel for ESLC management, standardizing MDT processes and guidelines, defining standardized datasets for data collection and internal MDT review, data sharing practices, and streamlining decision-making processes. This guidance document also provides a rational framework for improved standardized MDT care in ESLC (RISE-LC) to guide the implementation and optimization of MDT care in resource-constrained settings, aiming to improve timely diagnosis, treatment coordination, and patient outcomes.

Indexed as

Lung NeoplasmsPatient Care TeamDeveloping CountriesHumansNeoplasm StagingResource-Limited Settingsearly‐stagelow‐ and middle‐income countrieslung cancermultidisciplinary teamrecommendations

Identifiers

PMID42610673
PMCPMC13483319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.